Delisting riskPopularity #5,375
CytoMed Therapeutics (GDTC)
Develops donor-derived and iPSC-based cell therapies for cancer.
$0.9082
vs last close−0.00 (−0.20%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 29.98% | 3.55M ADS | |
|---|---|---|---|
| 6 holders · as of Jul 24, 2026 | |||
| Strategic holders | 69.12% | 8.18M ADS | |
| 4 holders · as of Mar 24, 2025 | |||
| Other | 0.90% | 107.0K ADS | |
| remainder | |||
11.83M ADS as of Sep 2, 2026 · holders as of their latest filing
The share count is from the company's Apr 2024 annual report; nothing newer is on file here.
13F
No 13F holders on record.
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Choo Chee Kong | 24.30% | 2.90M | 13D | Jul 24, 2026 |
| mDR LTD | 11.33% | 1.31M | 13G | Mar 24, 2025 |
| 28 Consultants Ltd | 7.62% | 880.3K | 13G | Mar 4, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 14, 2026 | Chee Kong Choodirector, 10 percent owner: | Purchase · 2 lots | 200,000 | $1.50 | 530,324 |
| Jul 20, 2026 | Chee Kong Choodirector, 10 percent owner: | Purchase · 2 lots | 200,000 | $1.50 | 630,324 |
| May 13, 2026 | Chee Kong Choodirector, 10 percent owner: | Purchase | 112,000 | $1.15 | 430,324 |
House and Senate disclosures
Not reported.